BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Aurigene Discovery Technologies Limited readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Aurigene Discovery Technologies L
 imited's drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03328078-2947@assetmemo.bio
DTSTAMP:20261121T005923Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Emavusertib: Phase 1/2 readout est. (NCT03328078)
DESCRIPTION:Emavusertib\, phase 1/2\, Primary Central Nervous System Lympho
 ma.\nStudy: CA-4948-101: Open-Label\, Dose Escalation and Expansion Trial 
 of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous
  System Lymphoma (R/R PCNSL)\nEstimated primary completion: July 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/emavusertib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT03328078
URL:https://assetmemo.bio/drug/emavusertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07271667-2947@assetmemo.bio
DTSTAMP:20261121T005923Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Emavusertib: Phase 2 readout est. (NCT07271667)
DESCRIPTION:Emavusertib\, phase 2.\nStudy: A Study of Emavusertib + An Appr
 oved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic 
 Lymphocytic Leukemia (CLL) and Other B-cell Malignancies\nEstimated primar
 y completion: November 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/emavusertib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07271667
URL:https://assetmemo.bio/drug/emavusertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
